Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 10:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 164 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo topical gel Clear all
Terminated Phase 3 Interventional

Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL

NCT06470451
View directory record Official record
Conditions
CTCL/ Mycosis Fungoides, CTCL, Mycosis Fungoides, Cutaneous T Cell Lymphoma
Interventions
Hypericin, Placebo
Drug
Lead sponsor
Soligenix
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
17
States / cities
Phoenix, Arizona • Scottsdale, Arizona • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo

NCT01426269
View directory record Official record
Conditions
Rosacea
Interventions
Doxycycline, Metronidazole, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 80 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
11
States / cities
Santa Monica, California • Coral Gables, Florida • Corbin, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 3, 2026, 10:49 PM EDT
Recruiting Phase 1 Interventional

Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

NCT06504160
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ShA9 Topical Gel, Hydrocortisone Ointment, Clobetasol Ointment, Fluocinonide Ointment, Placebo (Vehicle) Topical Gel, Triamcinolone Ointment
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
San Diego, California • Denver, Colorado • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 3, 2026, 10:49 PM EDT
Recruiting Phase 2 Interventional

A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex

NCT07027345
View directory record Official record
Conditions
Epidermolysis Bullosa Simplex
Interventions
5% TolaSure Topical Gel, Topical Placebo Gel
Drug
Lead sponsor
BioMendics, LLC
Industry
Eligibility
2 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Palo Alto, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 3, 2026, 10:49 PM EDT
Not listed Phase 2 Interventional

Topical 2% Povidone-Iodine Gel in Verruca Vulgaris

NCT04253912
View directory record Official record
Conditions
Warts
Interventions
VBP-245, Placebo Gel (no Povidone-Iodine)
Drug
Lead sponsor
Veloce BioPharma LLC
Industry
Eligibility
8 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Hunt Valley, Maryland • Plymouth Meeting, Pennsylvania • Sugarloaf, Pennsylvania + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 2 Interventional

A Safety and Efficacy Study of a Topical Gel for the Treatment of Mild to Moderate Psoriasis

NCT00593177
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
PTH (1-34) Gel / Placebo Gel
Drug
Lead sponsor
Manhattan Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
4
States / cities
San Diego, California • Ormond Beach, Florida • Fridley, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2008 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 3 Interventional Results available

A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo

NCT00350636
View directory record Official record
Conditions
Overactive Bladder
Interventions
Oxybutynin topical gel, Placebo topical gel
Drug · Other
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
789 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
63
States / cities
Birmingham, Alabama • Homewood, Alabama • Mobile, Alabama + 60 more
Source: ClinicalTrials.gov public record
Updated May 10, 2010 · Synced Oct 3, 2026, 10:49 PM EDT
Terminated Phase 1 Interventional

Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol

NCT01533376
View directory record Official record
Conditions
Sturge Weber Syndrome, Port-wine Mark
Interventions
Timolol, Preservative free artificial tear gel.
Drug
Lead sponsor
Wills Eye
Other
Eligibility
2 Years to 10 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Oct 3, 2026, 10:49 PM EDT
Recruiting Phase 2 Interventional

A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study

NCT06594393
View directory record Official record
Conditions
Epidermolysis Bullosa (EB), Dystrophic Epidermolysis Bullosa, Junctional Epidermolysis Bullosa
Interventions
TCP-25 gel, Vehicle (placebo)
Drug
Lead sponsor
Xinnate AB
Industry
Eligibility
4 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Safety and Efficacy of BGC20-0582 Lice Treatment Gel for Head Lice Infestation

NCT00528021
View directory record Official record
Conditions
Pediculus Humanus Capitis, Head Lice
Interventions
Placebo, BGC20-0582
Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
2 Years to 70 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Florida City, Florida
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 3, 2026, 10:49 PM EDT
Not listed Phase 2 Interventional

Topical KB105 for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)

NCT05735158
View directory record Official record
Conditions
Autosomal Recessive Ichthyosis
Interventions
KB105, Placebo
Biological · Other
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
6 Months and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rancho Santa Margarita, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 3 Interventional Results available

Comparison Between Podofilox Topical Gel 0.5% and Allergan's Condylox® Gel 0.5% for External Anogenital Warts

NCT03532776
View directory record Official record
Conditions
External Anogenital Warts
Interventions
Podofilox Gel 0.5%, Condylox Topical Gel 0.5%, Placebo Gel
Drug
Lead sponsor
Dermax SA
Industry
Eligibility
18 Years to 65 Years
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Miami, Florida • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029

NCT05428449
View directory record Official record
Conditions
Androgenetic Alopecia, Acne Vulgaris
Interventions
GT20029 Gel, GT20029 Gel Placebo
Drug
Lead sponsor
Suzhou Kintor Pharmaceutical Inc,
Industry
Eligibility
18 Years to 60 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
San Diego, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 2 Interventional

A 2 Week Study of Topical KD7040 in the Treatment of Postherpetic Neuralgia (PHN)

NCT00576108
View directory record Official record
Conditions
Postherpetic Neuralgia, Shingles, Herpes Zoster, Neuropathic Pain
Interventions
KD7040 Topical Gel, Placebo gel
Drug
Lead sponsor
Kalypsys, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 22, 2008 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 3 Interventional Results available

5% Topical Ibuprofen (IBU) for Ankle Sprain

NCT01945034
View directory record Official record
Conditions
Ankle Injuries
Interventions
Topical IBU twice daily, Placebo twice daily, Topical IBU three times daily, Placebo three times daily
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
19
States / cities
Sheffield, Alabama • Tucson, Arizona • Anaheim, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 3 Interventional

Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon

NCT00266669
View directory record Official record
Conditions
Raynaud's Disease
Interventions
Topical organogel with nitroglycerin
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
17
States / cities
Stanford, California • Denver, Colorado • Farmington, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2007 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 2 Interventional

Amelioration of Adverse Ocular Side Effects of Glaucoma Medications in Glaucoma Patients Using Topical GL101

NCT02656394
View directory record Official record
Conditions
Ocular Surface Disease
Interventions
GL101, Placebo
Drug
Lead sponsor
Glia, LLC
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Influence of Menthol Gel During Exercise With Heat

NCT05302804
View directory record Official record
Conditions
Acute Exercise, Heat Exposure
Interventions
Menthol Gel, Control Gel
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 1Phase 2 Interventional

Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial

NCT02349009
View directory record Official record
Conditions
Systemic Scleroderma
Interventions
C-82 Topical Gel, 1%, C-82 Topical Gel, Placebo
Drug
Lead sponsor
Prism Pharma Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Chicago, Illinois • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 2 Interventional

Iontophoretic Application of Acyclovir Gel to Treat Cold Sores

NCT00469300
View directory record Official record
Conditions
Herpes Labialis
Interventions
Iontophoretic delivery of acyclovir
Drug
Lead sponsor
Transport Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
810 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
13
States / cities
Birmingham, Alabama • Santa Rosa, California • Pinellas Park, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2008 · Synced Oct 3, 2026, 10:49 PM EDT
Terminated Phase 2 Interventional

Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa

NCT03578029
View directory record Official record
Conditions
Junctional Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa
Interventions
RGN-137, Placebo
Drug
Lead sponsor
Lenus Therapeutics, LLC
Industry
Eligibility
4 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Evanston, Illinois • Brooklyn, New York • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 1 Interventional

Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris

NCT04134273
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CLPG Topical Gel 1%, Clindamycin, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Oct 3, 2026, 10:49 PM EDT
Terminated Phase 4 Interventional Results available

TOM: Testosterone in Older Men With Sarcopenia

NCT00240981
View directory record Official record
Conditions
Sarcopenia, Hypogonadism, Muscular Diseases
Interventions
Topical testosterone gel 1% (active formulation), Topical gel (placebo formulation)
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
65 Years and older · Male only
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon

NCT00419419
View directory record Official record
Conditions
Raynaud's Disease, Scleroderma, Autoimmune Diseases
Interventions
Topical AmphiMatrix with nitroglycerin (MQX-503)
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
6
States / cities
Stanford, California • Farmington, Connecticut • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated May 30, 2007 · Synced Oct 3, 2026, 10:49 PM EDT